Selumetinib Clinically Improves NF1-Associated Neurofibromas

Article

The MEK inhibitor selumetinib showed clinical responses in the plexiform neurofibromas of adult patients with neurofibromatosis type 1.

The MEK inhibitor selumetinib showed clinical responses in the plexiform neurofibromas of adult patients with neurofibromatosis type 1 (NF1)-an indication which currently has no approved therapies available, according to new study findings. 

The phase II results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, this week in Boston.

The researchers said patients with NF1 develop benign and malignant tumors increasingly throughout their lifetimes – and especially the particular kind of nerve tumors they studied. 

“Twenty to 50% of patients with NF1 develop plexiform neurofibromas, which are tumors that form in peripheral nerves,” said Geraldine O’Sullivan Coyne, MD, PhD, of the National Cancer Institute in Bethesda, Maryland. “While these are not cancerous, they are at risk for developing into aggressive cancers.”

The open-label, single-site study has enrolled 26 patients between 18 and 60 years of age (median age of 33), as of this past August. The target response rate they reported at the outset was 45%. 

The selumetinib was administered in 50 mg doses twice daily continuously for 28-day cycles. Of the 21 evaluable patients, 71% had a partial response (based on a 20% volume decrease). Twenty-one patients remain in the study, with 4 patients discontinuing treatment based on adverse effects or other reasons. The grade 3 drug-related toxicities included transaminitis (5 patients, 23%), rash (4 patients, 19%), and pancreatic enzyme elevation (4 patients, 19%). 

The goal is to see if these adult results translate to pediatric patients, said O’Sullivan Coyne. 

 

“We hope the results in adults will parallel those reported in pediatric populations,” she added. 

Recent Videos
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content